Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Adverum Biotechnologies Inc (ADVM) USD0.0001

Sell:$2.22 Buy:$2.30 Change: $0.05 (2.19%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.05 (2.19%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.05 (2.19%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.

Contact details

800 Saginaw Drive
United States
+1 (650) 2726269

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$220.78 million
Shares in issue:
98.13 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Laurent Fischer
    President, Chief Executive Officer, Director
  • Jack Thrift
    Interim Chief Financial Officer
  • Peter Soparkar
    Chief Operating Officer
  • Angela Thedinga
    Chief Technology Officer
  • Brigit Riley
    Chief Scientific Officer
  • Jon Williams
    Vice President - Clinical Affairs
  • Julie Clark
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.